Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial.

Effect of Nonmyeloablative Hematopoietic Stem Cell Transplantation vs Continued Disease-Modifying Therapy on Disease Progression in Patients With Relapsing-Remitting Multiple Sclerosis: A Randomized Clinical Trial. JAMA. 2019 01 15; 321(2):165-174.

View in: PubMed

subject areas

Adolescent
Adult
Antilymphocyte Serum
Combined Modality Therapy
Cyclophosphamide
Disease Progression
Female
Hematopoietic Stem Cell Transplantation
Humans
Immunologic Factors
Immunosuppressive Agents
Male
Middle Aged
Multiple Sclerosis, Relapsing-Remitting
Young Adult